MARKET

SBBP

SBBP

Strongbridge
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.890
-0.020
-1.05%
Pre Market: 2.010 +0.12 +6.35% 08:52 10/30 EDT
OPEN
1.890
PREV CLOSE
1.910
HIGH
1.980
LOW
1.870
VOLUME
422
TURNOVER
--
52 WEEK HIGH
4.630
52 WEEK LOW
1.430
MARKET CAP
123.73M
P/E (TTM)
-1.9438
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 29)
Benzinga · 55m ago
TWTR, OPK, MHK and TRUP among after-hours movers
Gainers: [[TRUP]] +16%. [[EQ]] +15.8%. [[PLT]] +14.8%. [[MHK]] +12.3%. [[SBBP]] +10%.Losers: [[AXGT]] -41%. [[COLM]] -16.4%. [[TWTR]] -15.8%. [[UUU]] -12.5%. [[OPK]] -8.3%.
Seekingalpha · 15h ago
Strongbridge Biopharma EPS beats by $0.01, beats on revenue
Strongbridge Biopharma (SBBP): Q3 Non-GAAP EPS of -$0.12 beats by $0.01; GAAP EPS of -$0.06 beats by $0.20.Revenue of $8.1M (+42.6% Y/Y) beats by $0.66M.Shares +3.17%.Press Release
Seekingalpha · 16h ago
Strongbridge Biopharma Q3 EPS $(0.18) Misses $(0.14) Estimate, Sales $8.07M Beat $7.24M Estimate
Strongbridge Biopharma (NASDAQ:SBBP) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 28 percent increase over losses of $(0.25) per share
Benzinga · 17h ago
Strongbridge Biopharma Plcto Host Earnings Call
ACCESSWIRE · 17h ago
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 1d ago
Crinetics Pharma lead drug successful in mid-stage acromegaly study
A Phase 2 clinical trial, ACROBAT Edge, evaluating Crinetics Pharmaceuticals' (CRNX) lead candidate paltusotine (formerly CRN00808) for the treatment of acromegaly met the primary endpoint. Specifically, once-daily oral doses of
Seekingalpha · 4d ago
Insider Buys Strongbridge Biopharma's Stock
Shares of Strongbridge Biopharma Inc (NASDAQ:SBBP) increased by 2.4% from the previous closing price. Gill David N filed a Form 4 with the SEC on Monday, September 28. The insider bought 8,000 shares at an average price of $2.13. After the transaction, the executive's stake in Strongbridge Biopharma Inc.
Benzinga · 09/28 15:07
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SBBP. Analyze the recent business situations of Strongbridge through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SBBP stock price target is 8.29 with a high estimate of 18.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 97
Institutional Holdings: 28.39M
% Owned: 43.36%
Shares Outstanding: 65.47M
TypeInstitutionsShares
Increased
25
2.40M
New
21
754.22K
Decreased
20
1.03M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.19%
Pharmaceuticals & Medical Research
+0.17%
Key Executives
Chief Executive Officer
John Johnson
Chief Financial Officer
Robert Lutz
Chief Operating Officer
Richard Kollender
Other
Frederic Cohen
Other
Scott Wilhoit
Secretary
Stephen Long
Lead Director/Independent Director
Garheng Kong
Independent Director
David Gill
Independent Director
Jeffrey Sherman
Independent Director
Marten Steen
Independent Director
Hilde Steineger
Independent Director
Mårten Steen
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SBBP
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Strongbridge Biopharma plc stock information, including NASDAQ:SBBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SBBP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SBBP stock methods without spending real money on the virtual paper trading platform.